Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 4/20 | 0.60 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.60 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3973208 | 0.83 | SLC9A1 (0.54) | SLC9A1SLC9A2HSP90AA1HSP90AB1F10 | |
| SCHEMBL18929891 | 0.81 | SLC9A1 (0.71) | SLC9A1SLC9A2CNR2 | |
| SCHEMBL8582480 | 0.79 | SLC9A1 (0.47) | SLC9A1SLC9A2HSP90AA1HSP90AB1F10 | |
| Cariporide SCHEMBL39639 | 0.78 | SLC9A1 (0.61) | SLC9A1SLC9A2F10CNR2PRSS1 | |
| Guanidine SCHEMBL6134569 | 0.77 | SLC9A1 (0.59) | SLC9A1SLC9A2CNR2PRSS1 | |
| Cariporide SCHEMBL6261845 | 0.77 | SLC9A1 (0.63) | SLC9A1SLC9A2F10CNR2PRSS1 | |
| Cariporide SCHEMBL221094 | 0.77 | SLC9A1 (0.63) | SLC9A1SLC9A2F10CNR2PRSS1 | |
| Cariporide SCHEMBL220085 | 0.77 | SLC9A1 (0.60) | SLC9A1SLC9A2F10CNR2PRSS1 | |
| Cariporide SCHEMBL1229789 | 0.77 | SLC9A1 (0.60) | SLC9A1SLC9A2F10CNR2PRSS1 | |
| SCHEMBL3968070 | 0.76 | SLC9A1 (0.64) | SLC9A1SLC9A2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-7082234-A | — | — | None | — | — | JP | disclosed |
| EP-0921117-B2 | Acylguanidines | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-01-07 | — | — | EP | disclosed |
| US-20040044081-A1 | Diacyl-substituted guanidines, a process for their preparation, their use as medicament or diagnostic aid, and medicament containing them | HOECHST AKTIENGESELLSCHAFT | 2004-03-04 | — | — | US | disclosed |
| EP-0921117-B1 | Acylguanidines | AVENTIS PHARMA GMBH (DE) | 2003-12-10 | — | — | EP | disclosed |
| US-6632840-B1 | Inhibiting the Na+/H+ exchanger, treating at least one of arrhythmias and shock | HOECHST AKTIENGESELLSCHAFT (DE) | 2003-10-14 | — | — | US | disclosed |
| US-6436999-B1 | REACTING GUANIDINE AND CARBOCYCLIC ACIDS, TO FORM COMPOUNDS LIKE BIS(3-METHYLSULFONYL-4-I-PROPYLBENZOYL)GUANIDINE, USED FOR PROPHYLAXIS OF CARDIOVASCULAR DISORDERS AND AS PRODRUGS FOR SODIUM CHANNEL MODULATORS TO CONTROL BLOOD PRESSURE | HOECHST AKTIENGESELLSCHAFT (DE) | 2002-08-20 | — | — | US | disclosed |
| EP-0640587-B1 | Diacyl substituted guanidins, process for their preparation, their use as medicament or diagnostic reagent and medicament containing them | HOECHST AG (DE) | 1999-12-29 | — | — | EP | disclosed |
| EP-0921117-A2 | Acylguanidines | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-06-09 | — | — | EP | disclosed |
| JP-H0782234-A | DIACYL-SUBSTITUTED GUANIDINE, PREPARATION THEREOF, ITS USE AS DRUG OR DIAGNOSTIC AGENT AND DRUG CONTAINING IT | HOECHST AG | 1995-03-28 | — | — | JP | disclosed |
| EP-0640587-A1 | Diacyl substituted guanidins, process for their preparation, their use as medicament or diagnostic reagent and medicament containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044081-A1 | Diacyl-substituted guanidines, a process for their preparation, their use as medicament or diagnostic aid, and medicament containing them | ADRA1B, ADRA1A, HYOU1 | SLC9A1 37/4885SLC9A2 112/4885HSP90AA1 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.